Bracket Strengthens Global Growth and Development Strategy with New Chief Commercial Officer, Christopher Crucitti

WAYNE, Pa., — Bracket, a leading clinical trial technology and specialty services provider, today announced the addition of Christopher Crucitti, Chief Commercial Officer to its global executive team. Crucitti joins Bracket as an experienced commercial leader in clinical and R&D services.

Crucitti brings industry-recognized experience, knowledge and integrity to Bracket’s leadership team as well as notable accomplishments in training and motivating other commercial professionals to provide a high level of customer service and overall performance. He will be responsible for the global commercial strategy and development of Bracket’s electronic clinical outcomes assessments (eCOA) and patient engagement platform, Randomization and Trial Supply Management (RTSM), Rater Training and Quality Assurance as well the Company’s expanding mobile suite for patient diary and analytics, among others.

“It’s with great excitement that we welcome Chris to our leadership team,” said Jeff Kinell, CEO at Bracket. “Chris brings an impressive resume in clinical commercial strategy to Bracket and has joined us at a pivotal time, as we continue to position ourselves competitively in the global marketplace through the increased use of Bring Your Own Device mobile solutions for patient engagement. We look forward to the unique and seasoned perspective Chris will bring to our team and global commercial strategy.”

Prior to joining Bracket, Crucitti served as Chief Commercial Officer at Science Exchange, a world-leading marketplace for outsourced research and as Executive Vice President, Global Business Development at Worldwide Clinical Trials, Inc., a global CRO that provides full-service drug development services to the pharma and biotech industries. Crucitti also held senior roles at InVentiv Health Clinical and i3 Research, a pharmaceutical services company that provides integrated solutions throughout the product lifecycle.

“I’m extremely excited to join Bracket, with its many smart and committed team members, leveraging my experience in clinical development services and technology to further optimize our commercial growth strategy,” said Crucitti, Chief Commercial Officer at Bracket. “With recent and imminent expansion on the horizon, the ability to communicate how our suite of technologies and solutions empower patient engagement to ultimately improve outcomes will be paramount; I look forward to the challenge and the many opportunities to expedite the process of getting meaningful treatments in the hands of patients that need them.”

Crucitti earned his Masters of Science in Health Management from American University and his Bachelors of Science in Cardiac Rehabilitation and Exercise Science from Ithaca College.

About Bracket
Bracket, with ten offices and more than 800 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket SmartSupplies™ is a proven platform for improving a clinical supply chain. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs.

Bracket Acquires mProve Health to Radically Advance Patient Engagement in Clinical Trials

Wayne, Pa, — Bracket, a leading clinical trial technology and specialty services provider, today announced the strategic acquisition of mProve Health Inc. (mProve), a leading provider of mobile technologies for life science companies. The acquisition centers on both companies’ support of tech-enabled clinical trials that improve patient engagement through the use of “Bring Your Own Device” mobile tools in clinical trials.

Early-to-market with Electronic Clinical Outcomes Assessments (eCOA) and the first Randomization and Trial Supply Management (RTSM) mobile application, Bracket is at the forefront of digitization in clinical trials. Bracket helps biopharmaceutical sponsors and CROs increase the power of their data and identified a need to bring greater accuracy through technology. Included in mProve’s suite of regulatory compliant mHealth solutions is mPulse, an Electronic Patient-Reported Outcomes (ePRO) platform for enabling data collection via standalone native mobile apps or SMS text.  Other apps will enable communication with doctors and provide reminders and education.

In a recent report by KNect365, 94% of clinical trials professionals surveyed are looking to increase the utilization of mHealth, surpassing big data (86%) and cloud technology for EMRs (84%). These findings, among others, indicate mHealth technology as one of the most powerful opportunities in clinical trials. While mainstream eCOA providers are challenged to retrofit their systems to support emerging mHealth technologies and the BYOD movement, Bracket is now positioned for success with native mHealth capability.

“We are excited to announce the acquisition of mProve as we take a major step forward in our support of tech-enabled clinical trials,” said Jeff Kinell, CEO of Bracket. “As an early adopter of mHealth and BYOD, we recognize how these movements empower patients to become partners in their trials, and subsequently, deliver more accurate PRO and increase the likelihood of a successful trial.”

“This acquisition is an opportunity to bring the shared visions of mProve and Bracket into focus,” said Jeff Lee, CEO of mProve. “Both organizations center on improving patient engagement and driving adoption of the mHealth to do so. Together, we are well situated for a future of tech-enabled clinical trials.”

David Golde, Director at Genstar Capital, commented, “We are excited to be supporting Bracket’s first acquisition under Genstar ownership. Combined, Bracket and mProve’s solutions will deliver increased value to clinical trials through the greater use of technology. We look forward to working with Bracket management to continue pursuing strategic acquisitions that allow Bracket to better serve its customers.”

About mProve Health
mProve Health is a leading provider of mobile technologies for life science companies, helping them connect better with patients. The company offers industry-grade, regulatory compliant mobile solutions for patient recruitment, patient engagement, and electronic clinical outcome assessments (eCOA). mProve’s applications are used by 18 of the top 20 pharmaceutical companies, 15,000 clinical research sites in over 60 countries, and they are translated in over 50 languages to support patients across the globe. The company was founded in 2010 by Jeff Lee, CEO, an entrepreneur and mobile engagement strategist who founded three prior successful ventures, and Denis Curtin, PhD, CSO, a pharmacologist and pharmaceutical industry veteran. Learn more at www.mprove.com.

About Bracket
Bracket, with nine offices and more than 700 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket SmartSupplies™ is a proven platform for improving a clinical supply chain. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs. Learn more about Bracket at www.bracketglobal.com.

About Genstar Capital
Genstar Capital (www.gencap.com) is a leading private equity firm that has been actively investing in high quality companies for more than 25 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. Genstar manages funds with total capital commitments of approximately $9 billion and targets investments focused on targeted segments of the industrial technology, healthcare, financial services, and software industries.

Bracket Welcomes New Chief Technology Officer Sam Whitaker

Wayne, PA – Bracket, a leading clinical trial technology and specialty services provider, today welcomed Sam Whitaker as Chief Technology Officer (CTO) to its growing team. Whitaker joins Bracket’s leadership team bringing ten years of experience in clinical technology and global infrastructure innovation to the Company.

Whitaker will be responsible for Bracket’s global product strategy, management and innovation, technology development and engineering including architecture, user experience (UX), user interface (UI) and IT support functions. Whitaker will leverage his ten years’ experience as co-founder and CEO of Greenphire, the first clinical technology to bring payment technology to the clinical environment.

During his tenure at Greenphire, Whitaker invented and successfully commercialized the first clinical trial payment technologies. The web-based applications were built on top of a global technology infrastructure, which he and his team designed to support the unique needs of sponsors, clinical research organizations (CROs) and sites and scaled to support more than 500 clients globally.

“Sam Whitaker joins Bracket with highly specific knowledge of clinical trial technology and a complete understanding of our technological vision,” said Jeff Kinell, CEO of Bracket. “As we continue to solidify our position as a global leader in clinical trial technology and specialty services, it’s imperative that we partner with our industry’s most innovative minds to lead and implement industry-wide advancements.”

Prior to Greenphire, Whitaker worked in the product division of Citigroup, designing technology solutions across verticals. He graduated from the University of Pennsylvania.

About Bracket

Bracket, with nine offices and more than 700 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket SmartSupplies™ is a proven platform for improving a clinical supply chain. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs.

Bracket Expands Team with Industry Leader Dr. Amir Kalali

Wayne, PA – Bracket, a leading clinical trial technology and specialty services provider, today introduced Amir Kalali, MD, as its Executive Advisor for Global Strategy . Dr. Kalali joins Bracket as a recognized leader in drug development methodology and technological innovation.

Dr. Kalali will work with Bracket’s leadership to help identify innovative technologies to support the evolution of its integrated growth. In addition, Dr. Kalali will assist in the acceleration of growth in Bracket’s CNS product lines in other fields of medicine.  He is Professor of Psychiatry at University of California San Diego, Editor of the journal Innovations in Clinical Neuroscience, and the Lead Editor of the book Essential CNS Drug Development, published by Cambridge University Press. He has authored over 150 peer-reviewed publications.

Previously, Dr. Kalali was Global  Head of the Neuroscience Center of Excellence at Quintiles IMS, where he was responsible for the enterprise-wide strategy for neuroscience, encompassing drug development and healthcare services.

Recognized globally as a leader in drug development and healthcare with an emphasis on  innovation, collaboration, and the intersection with new technology, Dr. Kalali was the Founding Chairman of the Executive Committee of the International Society for CNS Drug Development  (ISCDD), a founding member of the International Society for CNS Clinical Trials and  Methodology (ISCTM), where he serves on Executive Committee, the Scientific Committee, and  previously chaired the Membership and Publication Committees. He is also a founder and Co- Chair of the Scientific Program Committee of the CNS Summit, and serves on the Scientific Program Committee of the American College of Neuropsychopharmacology. Dr. Kalali regularly presents at national and international scientific meetings, and lectures  frequently on drug development, innovation, technology, digital medicine and health.  He is an advisor to the Center for Digital Transformation at the Paul Merage School of Business  at the University of California, Irvine.

“We are  thrilled  to welcome Dr. Kalali to Bracket,” said David G. Daniel, MD, Senior Vice President and Chief Medical Officer of Bracket. “Dr. Kalali’s depth and breadth of knowledge of clinical trial methodology and emerging technologies is unparalleled. We anticipate that Dr. Kalali will become a major contributor to Bracket’s  growth in eCOA, rater training and data quality monitoring solutions.” During his career, Dr. Kalali has been recognized five times by PharmaVOICE magazine as one of the 100 most inspiring leaders in life sciences. In 2014, he was awarded the PharmaVOICE Red Jacket Award in recognition of his career-long contributions to the industry.

Dr. Kalali earned his medical degree from the University of London and completed his psychiatry training at University College and Middlesex School of Medicine, University of London.

About Bracket
Bracket, with nine offices and more than 700 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket SmartSupplies™ is a proven platform for improving a clinical supply chain. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs.

Bracket Introduces Transformative IRT Solution, CUBE™, to Biotech and Pharma Sponsors

WAYNE, Pa — Bracket, a leading clinical trial technology and specialty services provider, announced today the release of CUBETM, a transformative interactive response technology (IRT) solution for the life sciences industry. Designed through an iterative user acceptance build experience, CUBE will be immediately available to qualifying biotechnology and pharmaceutical trial sponsors through Bracket.

The solution will enable biotech and pharma sponsors to utilize an innovative new solution to deploy studies in one to two weeks. It leverages an iterative user acceptance build experience to provide a rapid and advanced deployment methodology without the time and cost constraints of traditional IRT solutions. Key highlights of CUBE for biotech and pharma sponsors of any size include:

  • Accelerate times for sponsors and improves efficiency for CROs
  • Leverages Bracket’s full RTSM platform, but streamlines deployment through automation
  • Rapid project lifecycle lets sponsors experience the system prior to requirements approval
  • Reduce lengthy turnaround times for enhancements and in-study changes

“We’re so pleased to introduce CUBE to the life sciences marketplace and are confident that its easy-to-implement nature will improve the process of managing clinical supplies,” said Jeff Kinell, CEO at Bracket. “By deemphasizing requirement documents and prioritizing unique configuration needs, CUBE will undoubtedly evolve the paradigm of how sponsors collaborate to deploy IRT.”

The platform’s iterative UAT process allows study teams to visualize the RTSM system during the kick off meeting. This accelerates timelines for sponsors and improves efficiency for CROs. CUBE also leverages Bracket’s full RTSM platform, but streamlines the deployment of configuration profiles through automation. It’s intended to support most trial design constructs.

For more information, please visit www.bracketglobal.com/CUBE/.

About Bracket
Bracket, with nine offices and more than 700 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket SmartSupplies™ is a proven platform for improving a clinical supply chain. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs.

Bracket Announces Launch of Cloud-Based Version of SmartSupplies

Wayne, Pa — Bracket, a leading clinical trial technology and specialty services provider, today announced the launch of a cloud-based service for SmartSupplies, its clinical trial inventory management software suite. This launch marks the first hosted solution of SmartSupplies since Bracket’s acquisition of CLINapps in 2016 and is applicable to all modules of the SmartSupplies suite.

SmartSupplies, an enterprise clinical trial material management software solution, provides end-to-end clinical inventory management for sponsors. The release of the cloud-based offering will enable companies without their own IT infrastructure and servers to easily and securely run and manage the application. Built atop Oracle Cloud Services, the cloud-hosted solution will facilitate enhanced integration with other eClinical systems as well as allow end users and clinical research associates (CRAs) to share data seamlessly and instantaneously without geographic constraints.

“We are pleased to introduce a cloud-based hosting option for SmartSupplies to our existing and new customers,” said Jeff Kinell, CEO of Bracket. “The benefits of cloud hosting continue to present themselves, especially as clinical trials worldwide rely more on immediate collaboration across sites.”

Bracket’s hosted SmartSupplies solution is competitively priced and provides a cost-effective alternative for sponsor companies deploying the enterprise solution. This cloud-based option allows sponsors to eliminate in-house hardware maintenance and management for a reduced IT footprint.  Other advantages include:

  • Reducing outsourced hosting, off-shore contractors and vendors for decreased third-party costs;
  • Enabling proactive support and system health-checks from Bracket’s support team;
  • Facilitating better integration with other eClinical systems and collaboration across sites; and
  • Ensuring a well-maintained regulatory environment and robust business continuity.

The transition of SmartSupplies to the cloud is seamless for existing customers, causing no disruption to the end user.

“Offering customers the option of cloud hosting for SmartSupplies was born out of necessity,” said Kinell. “We want sponsors to focus their energy and efforts on running clinical trials, not on managing their IT infrastructure – and hosting SmartSupplies in the cloud will alleviate that burden.”

About Bracket
Bracket, with nine offices and more than 700 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket SmartSupplies™ is a proven platform for improving a clinical supply chain. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs.

Bracket Among the First Providers to Initiate BYOD ePRO Clinical Research Study in Japan

Wayne, Pa —Bracket, a leading clinical trial technology and specialty services provider, today announced the launch of a new Bring Your Own Device (BYOD) electronic patient-reported outcome (ePRO) study in Japan.  This study highlights the importance of BYOD use in clinical studies as an integral component of electronic clinical outcomes assessments (eCOA). Bracket is among the first to utilize BYOD in a randomized clinical trial in Japan.

The use of BYOD in clinical research is the next crucial stage in continuing to embrace the technology that has fundamentally improved the way studies are conducted. BYOD adoption is slowly gaining momentum, but the many ways it has enhanced the effectiveness of clinical research serve as an argument for why mobile support should become an essential element of other eCOA platforms.

Bracket’s own next-generation platform, Bracket eCOA™, integrates with several devices to support ePRO, eClinRO and eObsRO use, supplementing a BYOD approach. Allowing patients to collect and report data in a central location through easy-to-use mobile applications increases patient engagement and improves data quality.

“eCOA is an extremely important research tool and the increasing adoption of BYOD is highly beneficial for the industry on a global scale,” said Jeff Kinell, CEO at Bracket.

Bracket Patient Diary is a native app that allows patients in clinical trials to use their own smartphones to complete questionnaires about their symptoms, medication use, and quality of life. Bracket Patient Diary has been in use in clinical trials since 2014 and is available for Android and iOS.

About Bracket
Bracket, with nine offices and more than 700 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket SmartSupplies™ is a proven platform for improving a clinical supply chain. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs.

Bracket to Develop Electronic Versions of MDS-UPDRS and UDysRS for Parkinson’s Disease Trial Assessments

Wayne, PA., — Bracket, a leading clinical trial technology and specialty services provider, today announced an agreement with the International Parkinson and Movement Disorder Society (MDS), to develop electronic versions of the MDS-Unified Parkinson’s disease Rating Scale (MDS-UPDRS) and the Unified Dyskinesia Rating Scale (UDysRS). The migration of these complex scales to an electronic clinical outcome assessment (eCOA) format aims to improve trial conduct and data quality for Parkinson’s disease (PD) studies.

The increasing prominence of PD, a progressive disorder of the nervous system that affects movement, drove MDS to prioritize the update of its scales. Today more than 10 million people worldwide are living with the condition, and each year 60,000 people are newly diagnosed in the United States alone.

Bracket has extensive experience working with paper-and-pencil clinical outcomes in Parkinson’s disease and other movement disorders. Bracket is creating eCOA versions of the MDS-UPDRS and UDysRS to support efforts to improve data quality in these studies. Both scales require careful clinical interviews of patients, and by migrating these instruments from paper records to eCOA platforms, investigators and pharmaceutical sponsors will be equipped with a more effective method for using these outcomes in clinical trials.

“Clinical trials in Parkinson’s disease and other movement disorders are extremely complex and have a high failure rate,” said Jeff Kinell, CEO of Bracket. “Fortunately, digitization in clinical trials is improving results, as the logic of eCOA streamlines scoring protocols and compliance. We’re proud to partner with MDS to advance PD trials and help address the growing prevalence of the disease at the ground level.”

The UPDRS was developed in the 1980s and is the most widely used rating scale for PD in clinical trials. The revision, known as the MDS-UPDRS, was released in 2008 and measures mentation, behavior and mood, activities of daily living and motor functions. The UDysRS evaluates involuntary movements associated with treated PD, measuring on-dyskinesia, off-dystonia, impairment and disability.

The MDS-UPDRS and UDysRS scales are prime candidates for digitization as eCOA will streamline specific trial protocols, including the addition of time stamps associated with administration to ensure scales are administered appropriately. Additionally, eCOA will simplify calculations on how much time subjects report experiencing dyskinesia, dystonia and an “off” state.

About Bracket
Bracket, with nine offices and more than 700 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket SmartSupplies™ is a proven platform for improving a clinical supply chain. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs.

Bracket Welcomes Jennifer Peters as Senior VP and General Manager to Scientific Services

WAYNE, PA — Bracket, a leading clinical trial technology and specialty services provider, today announced the addition of Jennifer Peters to its growing team as the Company’s new Senior Vice President and General Manager for the Scientific Services division. In this role, Ms. Peters will be responsible for Bracket’s work in Rater Training, Quality Assurance, and Electronic Clinical Outcomes Assessments (eCOA.) Ms. Peters joins Bracket with a strong skillset and demonstrated record building technology-based businesses in life sciences.

With more than 14 years of life sciences industry experience, Ms. Peters most recently served as a Founder and Chief Experience Officer of Greenphire, a global provider of disruptive clinical trials payment and process optimization technology products serving pharmaceutical sponsors, biotech companies and CROs. She led Greenphire from an idea-stage startup, with three founding employees at its inception in October 2007 to a global technology enterprise with more than 100 employees and 500+ clients when it was sold to a private equity firm in 2014.

“We’re very fortunate to have someone with Ms. Peters’ background join our senior leadership team at a time when we are experiencing solid growth due to the adoption of technology and deployment of proprietary methodologies,” said Jeff Kinell, CEO at Bracket. “Our growth has created the need to be innovative in both the way we’re organized and the way we deliver on our commitments to clients. We are confident that Ms. Peters will bring fresh ideas to help lead us to continued success.”

Prior to her tenure at Greenphire, Ms. Peters held a series of progressively senior leadership positions beginning in 2002 at Transperfect Translations, a global provider of translation services and localization technology to clinical trial sponsors and CROs.

Ms. Peters holds a Master’s of Science degree from Pace University and will be based in Bracket’s Wayne, PA headquarters.

About Bracket
Bracket, with nine offices and more than 700 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs.

Bracket Welcomes Clinical Vice President Lewis Fredane, MD to Global Team

Wayne, PA – Bracket, a leading clinical trial technology and specialty services provider, announced the addition of Clinical Vice President Lewis M. Fredane, MD to its global team. A board certified neurologist with more than 30 years of clinical research experience, Fredane brings a strategic combination of clinical and industry research expertise to his new role.

As Clinical Vice President, Dr. Fredane will serve as the Therapeutic Area Leader for neurology and will oversee Bracket’s eCOA, Rater Training, and Quality Assurance work in this important therapeutic area.

“Neurology, especially neurodegenerative and developmental disorders are a critical focus for Bracket and Dr. Fredane’s impressive background and experience will be instrumental to our progress in these areas,” said David G. Daniel, MD, Senior Vice President and Chief Medical Officer at Bracket.

“We look forward to the knowledge and leadership Dr. Fredane will bring to Bracket and warmly welcome him to the team.”

Prior to joining Bracket, Dr. Fredane served as a practicing neurologist and clinical assistant professor of Neurology at Drexel University College of Medicine in Philadelphia, Pennsylvania. He has worked in pharmaceutical drug development at several companies including at Sanofi/Genzyme Pharmaceuticals, Meda Pharmaceuticals and with CRO Omnicare Clinical Research. He also maintains extensive experience in medical affairs and has published research on multiple sclerosis, pain management and transplantation.

“I am so pleased to join the esteemed Bracket team and combine my diverse experience in neurology with the global platform, innovative tools and intelligence already set forth by this organization,” said Dr. Fredane.

Dr. Fredane received his medical degree from Albert Einstein College of Medicine and completed his training with a residency in Neurology at Duke University. He completed fellowships in Clinical Immunology at St. Luke’s-Roosevelt Hospital Center in New York and in Immunology at Yale University School of Medicine in New Haven, Connecticut through a research fellowship with the National MS Society.

About Bracket
Bracket, with nine offices and more than 700 employees worldwide, is a clinical trial technology and specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs.